Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (91-100 of 208) with videos related to

Pageof 21
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 26, 2018
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case reportYanira Ruiz-Heredia, Beatriz Sanchez-Vega, Santiago Barrio, et al.
Cancer|March 27, 2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myelomaRuth Seggewiss-Bernhardt, Ralf C Bargou, Yeow Tee Goh, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.
Blood|August 24, 2011
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Cancer Cell|February 5, 2008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignanciesMarta Chesi, Davide F Robbiani, Michael Sebag, et al.
Blood|December 10, 2009
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6Rodger E Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2026
Medication-related osteonecrosis of the jaw: incidence and risk factors in multiple myeloma patients undergoing pre-autologous stem cell transplant dental extractionsJi-Eun Deanna Son, Joo Wan James Kim, Sung-Ha Son, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Blood Cancer Discovery|March 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaRintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, et al.
Pageof 21

Showing results (91-100 of 208) with videos related to

Sort By:
Pageof 21
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 26, 2018
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case reportYanira Ruiz-Heredia, Beatriz Sanchez-Vega, Santiago Barrio, et al.
Cancer|March 27, 2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myelomaRuth Seggewiss-Bernhardt, Ralf C Bargou, Yeow Tee Goh, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.
Blood|August 24, 2011
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Cancer Cell|February 5, 2008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignanciesMarta Chesi, Davide F Robbiani, Michael Sebag, et al.
Blood|December 10, 2009
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6Rodger E Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2026
Medication-related osteonecrosis of the jaw: incidence and risk factors in multiple myeloma patients undergoing pre-autologous stem cell transplant dental extractionsJi-Eun Deanna Son, Joo Wan James Kim, Sung-Ha Son, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Blood Cancer Discovery|March 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaRintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, et al.
Pageof 21